Alumina Ceramic Prosthesis for Malignant Bone Tumors in Distal Femur. Postoperative Evaluation with more than 6-year Follow-up.

AbstractIntroduction: In order to diagnose and stage malignant bone tumors, the pathologic examination of harvested pieces with immunohistochemistry test is necessary; they also provide information regarding the prognosis on a medium to long term. Among tissular biomarkers with potential predictive value, a raised Ki-67 protein level is used to determine the risk of local recurrence or metastasis.Material and method: This study was performed on 50 patients with primary malignant bone tumors admitted in the Traumatology and Orthopedy Department of University Emergency Hospital, Bucharest. Patients repartition according to diagnosis was the following: 21 patients with osteosarcoma, 18 patients with chondrosarcoma, 6 patients with Ewing sarcoma, 3 patients with malignant fibrous histiocytoma, and 2 with fibrosarcoma. The follow-up period was between 12 and 72 months with a mean of 26 months.Results: Patients were aged between 18 and 77 years old, with a mean age of 41,36. There were 22 women and 28 men. No sex or age difference was notable for the tumor outcome. After calculating the Ki-67 LI, 36 patients were included in the high-risk group (Ki-67 LI > 25%), while 14 had a low risk for metastasis and local relapse (Ki-67 < 25%). The low-risk patients had chondrosarcoma (8 patients), osteosarcoma (5 patients), and fibrosarcoma (1 patient). During the follow-up, 8 patients, all belonging to the high risk group, developed metastasis, while 5 patients developed local recurrences; 4 patients who relapsed belonged to the high risk group and 1 to the low risk group. Metastases developed in 3 patients with osteosarcoma, 2 with Ewing sarcoma, 2 with chondrosarcoma and 1 patient with fibrosarcoma. Most metastases occurred within one year after surgery. The other fibrosarcoma patient developed local recurrence after 6 months, while the other local recurrences occurred in osteosarcoma patients (2 cases) and 1 in a Ewing sarcoma patient and chondrosarcoma patient.Conclusions: Our study concluded that while Ki-67 LI values are useful in determining the aggressivity of primary malignant bone tumors, it should always be used in conjunction with the clinical, imaging and anatomopathological diagnosis methods in order to accurately predict the patients’ outcome.

Download Full-text

Solid organ second malignant neoplasms among children diagnosed with malignant bone tumors treated on Children Cancer Study Group/Pediatric Oncology Group protocols after 1980

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.9007 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 9007-9007

Author(s):

R. Goldsby ◽

C. Burke ◽

R. Nagarajan ◽

T. Zhou ◽

Z. Chen ◽

...

Keyword(s):

Bone Tumors ◽

Univariate Analysis ◽

Primary Diagnosis ◽

Malignant Neoplasms ◽

Solid Organ ◽

Malignant Bone Tumors ◽

Entire Cohort ◽

Second Malignant Neoplasms

9007 Background: The growing number of individuals surviving childhood cancer has increased the awareness and recognition of long-term sequelae. One of the most worrisome complications following cancer therapy is the development of second malignant neoplasms (SMN), in particular, late-occurring solid second malignancies related radiation therapy. Methods: We describe the incidence of solid organ SMN in survivors of pediatric malignant bone tumors (MBT) treated on legacy CCG/POG protocols from 1980 to 2005. This retrospective cohort study included 2,842 patients, 1,686 treated for osteosarcoma (OS) and 1,156 treated for Ewings Sarcoma (ES). The cohort included 56% males and 44% females, with a median age at primary diagnosis of 13 years. The median length of follow-up was 4.3 years (range: 0 to 20.9 years). Results: At the time of the analysis, 64% of patients in this study are alive. Seventeen patients with solid organ SMN were identified, and included three patients with breast cancer, three with malignant fibrous histiocytoma, two with osteosarcoma, and 9 patients with other solid organ malignancies. The standardized incidence ratio (SIR=observed/expected cases) was 2.9 (95% confidence interval [CI], 1.4–5.4) for patients treated for OS and 5.0 (95%CI 2.6–9.4) for patients treated for ES. The median time from diagnosis to develop solid organ SMN was 7 years (range: 1 to 13 years). The 10-year cumulative incidence of solid organ SMN for the entire cohort was 1% (95%CI 0.6–2%). In univariate analysis, treatment with etoposide, cyclophosphamide or radiotherapy were each associated with a higher than expected incidence of cancer with SIR of 4.8 (95% CI, 2.5–9.5), 5.8 (95% CI, 3.5–9.5) and 4.1 (95% CI, 2.4–7.1), respectively. Conclusions: Solid organ SMNs are rare after treatment for OS and ES, although higher in patients treated for ES. Recurrence remains the most significant problem for patients diagnosed with MBT and development of improved therapies with fewer long-term consequences remains paramount. However, solid organ cancers are likely to increase with longer follow-up. Therefore, surveillance should focus on monitoring for both recurrence of primary malignancies and development of SMN. No significant financial relationships to disclose.

Download Full-text

Polyethylene Endoprostheses for the Treatment of Malignant Bone Tumors: A Long-Term Follow-Up Study

Limb Salvage ◽

10.1007/978-3-642-75879-9_37 ◽

1991 ◽

pp. 271-275

Author(s):

O. P. De Camargo ◽

N. R. B. De Oliveira ◽

R. Campos Filho ◽

A. T. Croci

Keyword(s):

Bone Tumors ◽

Malignant Bone Tumors ◽

Follow Up Study ◽

Long Term Follow Up

Download Full-text

Functional Evaluation of Limb Saving Operations in Patients with Malignant Bone Tumors of Distal Femur and Proximal Tibia.

Orthopedics & Traumatology ◽

10.5035/nishiseisai.46.1145 ◽

1997 ◽

Vol 46 (4) ◽

pp. 1145-1147

Author(s):

Hiroshi Ito ◽

Taro Kodama ◽

Takashi Sakou ◽

Norio Morimoto

Keyword(s):

Bone Tumors ◽

Distal Femur ◽

Proximal Tibia ◽

Functional Evaluation ◽

Malignant Bone Tumors

Download Full-text

A narrative review on the characteristics and treatment of benign and malignant bone tumors

Acta Facultatis Medicae Naissensis ◽

10.5937/afmnai2004325b ◽

2020 ◽

Vol 37 (4) ◽

pp. 325-336

Author(s):

Frydoni Bahrami ◽

Esmaeilnejad-Ganji Mokhtar

Keyword(s):

Bone Tumor ◽

Bone Tumors ◽

Distal Femur ◽

Proximal Tibia ◽

Health Workers ◽

The Body ◽

Malignant Bone Tumors ◽

Benign Bone Tumors ◽

Malignant Lesions ◽

Cartilaginous Tumors

Bone tumors, including benign and malignant lesions, are not metastatic; however, they may appear in any part of the body skeleton. Distal femur and proximal tibia (around the knee joint) are the most prevalent sites. Most benign bone tumors are cartilaginous tumors, known as osteochondromas. Based on the reports, benign bone tumors are more frequent than primary malignant ones. Malignant bone tumor is another type of bone tumor, which usually occurs within the first years of life. As a result, it can considerably affect the lives of patients and their families. These tumors consist of osteosarcoma, chondrosarcoma, and Ewing's sarcoma. This article discusses the epidemiology, characteristics, and treatment of the most important types of benign and malignant bone tumors. These data will be useful to the physicians and other health workers to better understand the conditions of bone tumors and their management.

Download Full-text

Bone Infarct Associated Osteosarcoma: Epidemiologic and Survival Trends

Oncology Research and Treatment ◽

10.1159/000521986 ◽

2022 ◽

Author(s):

Roberta Laranga ◽

Marco Focaccia ◽

Andrea Evangelista ◽

Enrico Lucarelli ◽

Davide Maria Donati ◽

...

Keyword(s):

Bone Tumors ◽

Distal Femur ◽

Case Reports ◽

Published Data ◽

Chemotherapy Treatment ◽

Literature Report ◽

Elective Treatment ◽

Bone Infarct ◽

Grade 3

Background Bone tumors are not a frequent occurrence and bone-infarct-associated sarcomas are even rarer. The prognosis of this disease is poor and its treatment remains a challenge. Nevertheless, hardly any analyses in literature report on secondary osteosarcoma (SO) on bone infarct and most of the data available do not provide sufficient details. We evaluated whether this condition could be further characterized and if prognosis could be influenced by the chemotherapy treatment. In particular, we sought to determine (1) the main features of this rare disease; (2) the overall survival (OS) rate; (3) the OS rate associated to chemotherapy treatment; (4) the correspondence between our results and published data in terms of survival. Methods We retrospectively reviewed patients admitted at Rizzoli Orthopedic Institute of Bologna between 1992 and 2018 (1465 total cases of osteosarcoma). We identified a list of 11 cases of SO on bone infarct (cohort 1). We conferred about the epidemiology, surgical and chemotherapy (ChT) treatment and surveillance of infarct-associated osteosarcoma showing the correlation to data present in literature, corresponding to 15 case reports published within 1962-2018 (cohort 2). Results (1) cohort 1 was made of 11 patients: six females and five males, median age was 55 years. Nine (81%) were grade 4, two (19%) grade 3. Tumor predominantly arise on distal femur (64%). Most of patients had localized osteosarcoma at the diagnosis (81%); resection surgery was the elective treatment (73%) followed by amputation (18%). Of 11 patients, seven received also ChT (64%). (2) Five-years OS was 62% (95% CI: 28-84). Median OS was 74 months (95% CI: 12-not reached). The cumulative incidence of cancer-related deaths (CICRD) was 37.7% (95% CI: 11.4-64.5) at 120 months. (3) In the group treated with only surgery OS was 50% at 5 years. For patients treated with any form of ChT, OS was 71% at 5 years (p=0.4773) and hazard ratio (HR) 0.56. The CICRD was 29% (at 2 years of follow-up. Instead, it was of 50% for patients treated only with surgery. (4) Median survival was 74 months and 19 months for cohort 1 and cohort 2 respectively (p=0.09). Data analysis showed a decreased HR for cohort 1 compared to cohort 2 (HR 0.378). Results confirmed also stratifying for age and ChT administration (HR 0.355). Conclusions Based on this work, our opinion is that the choice to undergo the patients to ChT combined to surgery could improve their prognosis.

Download Full-text

Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3436-0 ◽

2017 ◽

Vol 80 (6) ◽

pp. 1113-1131 ◽

Cited By ~ 9

Author(s):

Andrés Redondo ◽

Silvia Bagué ◽

Daniel Bernabeu ◽

Eduardo Ortiz-Cruz ◽

Claudia Valverde ◽

...

Keyword(s):

Clinical Practice ◽

Clinical Practice Guidelines ◽

Practice Guidelines ◽

Bone Tumors ◽

Malignant Bone Tumors

Download Full-text

INTRAOSSEOUS XANTHOMA OF THE DISTAL RADIUS — A CASE REPORT

Hand Surgery ◽

10.1142/s0218810414720149 ◽

2014 ◽

Vol 19 (02) ◽

pp. 223-226 ◽

Cited By ~ 1

Author(s):

Kannan Karuppiah Kumar ◽

Yorell Manon-Matos ◽

Sunil Thirkannad

Keyword(s):

Case Report ◽

Distal Radius ◽

Bone Tumors ◽

Rare Condition ◽

Malignant Bone Tumors ◽

History Of

An intraosseous xanthoma is a very rare condition. It has an aggressive appearance on radiographs mimicking primary or metastatic malignant bone tumors. We report a case of intraosseous xanthoma of the distal radius in a 51-year-old male with no history of hyperlipidaemia. To the best of our knowledge, this condition has not been reported so far in the wrist and forearm region. The lesion was successfully excised and at last follow-up, there were no signs of recurrence and patient has been symptom-free.

Download Full-text

Proximal Femur Versus Acetabular Extra-articular Resection of the Hip Joint for Primary Malignant Bone Tumors : A Retrospective Comparative Review of 33 Cases

10.21203/rs.3.rs-917462/v1 ◽

2021 ◽

Author(s):

Victor Housset ◽

Philippe Anract ◽

Antoine Babinet ◽

Guillaume Auberger ◽

David Biau

Keyword(s):

Hip Joint ◽

Proximal Femur ◽

Bone Tumors ◽

Malignant Bone Tumors ◽

Primary Bone Tumors ◽

Comparative Review ◽

Primary Bone ◽

The Mean ◽

Cumulative Probabilities

Abstract Introduction Extra-articular resection (EAR) of the hip joint is prone to significant complications and morbidity. Thus, this study evaluates the cumulative incidences and main reasons of reoperation following EAR of primary bone tumors of the hip to determine whether the outcomes are different between EAR of the pelvis and that of the proximal femur. Patients and methods Thirty-three patients presented with a PMBT of the proximal femur or pelvis were included in this study. Among all PMBTs, 58% originated from the pelvis and 42% were from the proximal femur. Twenty patients had chondrosarcomas (61%), 10 had osteosarcomas (30%), and 3 had sarcomas of another histological subtype (9%). Results The mean follow-up was of 76 months (range: 24–220 months). The cumulative probabilities of revision for any reason was 52% (95% confidence interval [CI]: 30%–70%) five years after surgery. The five-year cumulative probabilities of revision were 13% (95% CI: 4%–27%), 24% (95% CI: 10%–42%) and 34% (95% CI: 14%–56%) for mechanical, infectious and tumoral reasons, respectively. The five-year cumulative probabilities of revision for any reason were 78% (95% CI: 37%–94%) and 14% (95% CI: 2%–38%) for the pelvis and proximal femur, respectively ( p = 0.004). Posterior column preservation was significantly associated with more mechanical complications even after adjusting for the resection site ( p = 0.043). Conclusion Half of patients undergoing EAR of the hip joint for PMBT of the proximal femur or acetabulum will require another operation. EAR of the pelvis is associated with significantly worse outcome than EAR of the proximal femur.

Download Full-text